Advanced heart failure with reduced ejection fraction. Issue 3 (2nd July 2020)

• Record Type: Journal Article
• Authors: Hicks, Albert; Velazco, Jorge F.; Gohar, Salman; Seliem, Ahmed; Hall, Shelley A.; Michel, Jeffrey B.
• Is Part Of: Proceedings. Volume 33:Issue 3(2020)
• Page Start: 350
• Page End: 356
• Publication Date: 2020-07-02
• Subjects: Advanced heart failure -- angiotensin receptor blocker -- cardiac transplantation -- extracorporeal membrane oxygenation -- heart failure with reduced ejection fraction -- left ventricular assist devices -- neprilysin inhibition; Medicine -- Periodicals; Medicine; Medicine -- Periodicals; Periodicals; Electronic journals; 616.005
• DOI: 10.1080/08998280.2020.1765663
• Languages: English
• ISSNs: 0899-8280

Abstract

Abstract: Patients suffering advanced heart failure with reduced ejection fraction (HFrEF) account for a large portion of patients admitted to hospitals worldwide. Mortality and 30-day readmission rates for HFrEF are now a focus of value-based payment models, making management of this disease a priority for hospitals, physicians, and payers alike. Angiotensin-converting enzyme inhibitors have been the cornerstone of therapy for decades. However, with treatment, the prognosis for patients with advanced HFrEF remains poor. Fortunately, advances in medical therapy and mechanical support offer some patients improvement in both survival and quality of life. We review advances in short- and long-term mechanical support and explore changes to organ allocation for cardiac transplantation. In addition, we provide a guide to facilitate appropriate referral to an advanced heart failure team.